RT Book, Section
A1 Moore, Thomas A.
A2 Jameson, J. Larry
A2 Fauci, Anthony S.
A2 Kasper, Dennis L.
A2 Hauser, Stephen L.
A2 Longo, Dan L.
A2 Loscalzo, Joseph
SR Print(0)
ID 1160014440
T1 Agents Used to Treat Parasitic Infections
T2 Harrison's Principles of Internal Medicine, 20e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259644016
LK accessmedicine.mhmedical.com/content.aspx?aid=1160014440
RD 2024/04/18
AB Parasitic  infections  continue  to  afflict  more  than  half  of  the  world’s  population  and  impose  a  substantial  health  burden,  particularly  in  underdeveloped  nations,  where  they  are  most  prevalent.  The  reach  of  some  parasitic  diseases,  including  malaria,  has  expanded  over  the  past  few  decades  as  a  result  of  factors  such  as  deforestation,  population  shifts,  global  warming,  and  other  climatic  events.  Although  there  have  been  significant  advances  in  vaccine  development  and  vector  control,  chemotherapy  remains  the  single  most  effective  means  of  controlling  parasitic  infections.  Efforts  to  combat  the  spread  of  some  diseases  are  hindered  by  the  development  and  spread  of  drug  resistance,  the  limited  introduction  of  new  antiparasitic  agents,  the  proliferation  of  counterfeit  medications,  and,  most  recently,  profiteering,  which  has  dramatically  increased  the  cost  of  once-affordable  agents.  However,  there  are  good  reasons  to  be  optimistic.  Ambitious  global  initiatives  aimed  at  controlling  or  eliminating  threats  such  as  AIDS,  tuberculosis,  and  malaria  have  demonstrated  successes.  The  ongoing  efforts  of  multinational  partnerships  to  address  the  substantial  burden  imposed  by  neglected  tropical  diseases  have  generated  mechanisms  to  develop  and  deploy  effective  antiparasitic  agents.  In  addition,  the  development  of  vaccines  against  several  tropical  diseases,  including  malaria,  continues.